Skip to content
stoqly

BridgeBio Pharma, Inc.

BBIO Nasdaq Pharmaceutical Preparations Financials FY2017–FY2025

Revenue Total sales reported in the income statement.
$502M
126.3% vs prior year
Operating margin Operating income as a share of revenue.
−104.2%
163.0 pts
Net income Profit after all expenses, interest and tax.
−$733M
Free cash flow Cash from operations minus capital spending.
−$447M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
—
Market cap Last close times the latest diluted share count, so it is approximate.
—
P/E Last close divided by diluted earnings per share over the last four quarters.
—
On −$3.57 EPS (TTM)

What BridgeBio Pharma, Inc. does

No business description yet.

Legal name
BridgeBio Pharma, Inc.
Fiscal year ends
December 31, 2025
Latest annual report
10-K · Feb 24, 2026
Accession · CIK
0001743881-26-000009
0001743881

Revenue and margins

BridgeBio Pharma, Inc. had $502M of revenue in fiscal 2025, up 126.3% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was −$447M in fiscal 2025, −89.0% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

BridgeBio Pharma, Inc. returned $48.3M to shareholders in fiscal 2025. The diluted share count rose 2.9%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably BridgeBio Pharma, Inc. can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $788M$428M$376M$681M$587M
Debt incl. finance leases $432M$431M$446M$437M$2.0B
Interest coverage −12.3x−6.4x−7.5x−6.5x−9.9x
Current ratio 6.6x4.5x3.3x4.7x2.8x
Quick ratio 6.6x4.5x3.3x4.7x2.7x
Total assets $1.0B$623M$546M$919M$936M
Total liabilities $1.9B$1.9B$1.9B$2.4B$3.0B
Shareholders' equity −$870M−$1.3B−$1.4B−$1.5B−$2.1B
Net debt (− = net cash) −$355M$2.7M$70.5M−$244M$1.4B

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

—

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY17FY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕
Cash from operations is positive ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕
Return on assets rose — — ✕ ✕ ✓ ✕ ✕ ✓ ✕
Cash from operations exceeds net income ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Debt fell relative to assets — — ✕ ✓ ✕ ✕ ✕ ✓ ✕
Current ratio rose — — ✕ ✕ ✕ ✕ ✕ ✓ ✕
Share count didn't rise — ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕
Gross margin rose — — — — — ✓ ✕ ✓ ✕
Revenue rose relative to assets — — — ✕ ✓ ✓ ✕ ✓ ✓
F-score — / 3— / 41 / 72 / 83 / 83 / 91 / 96 / 92 / 9
Accruals ratio —−7.1%−6.4%−15.8%−10.3%−8.0%−21.5%−3.1%−30.9%
Altman Z'' —5.682.93−3.45−4.06−11.77−19.49−11.92−14.22

9 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue — — $40.6M $8.2M $69.7M $77.6M $9.3M $222M $502M
Gross profit — — — — $66.6M $74.2M $6.9M $218M $481M
Research and development $30.6M $140M $210M $337M $451M $399M $456M $506M $452M
Operating income −$43.9M −$184M −$266M −$474M −$577M −$512M −$607M −$593M −$523M
Interest expense $0.0M $2.5M $8.8M $36.7M $46.8M $80.4M $81.3M $91.0M $53.1M
Pretax income $43.8M $169M $289M $505M −$586M −$485M −$653M −$542M −$733M
Income tax — — — — — $0.0M $0.0M $1.2M $0.4M
Net income −$43.8M −$169M −$289M −$505M −$586M −$485M −$653M −$543M −$733M
Net income to common −$30.6M −$131M −$261M −$449M −$563M −$481M −$643M −$536M −$725M
Diluted EPS −$1.00 −$2.12 −$2.48 −$3.80 −$3.90 −$3.26 −$3.95 −$2.88 −$3.78
Diluted shares 0.03B 0.06B 0.11B 0.12B 0.14B 0.15B 0.16B 0.19B 0.19B
Cash flow
Cash from operations −$40.5M −$137M −$254M −$400M −$498M −$419M −$528M −$521M −$446M
Capital expenditure $0.5M $2.2M $2.6M $7.5M $13.2M $4.8M $1.3M $0.9M $1.1M
Free cash flow −$41.0M −$139M −$256M −$407M −$511M −$424M −$529M −$522M −$447M
Depreciation and amortization — — $0.9M $1.5M $5.8M $6.8M $6.5M $6.1M $5.4M
Stock-based compensation $1.8M $6.1M $21.4M $58.5M $99.5M $91.6M $109M $95.8M $133M
Share buybacks — — — $75.0M $200M $0.0M $0.0M $0.0M $48.3M
Dividends paid $1.2M — $1.0M — — — — — —
Dividends and buybacks $1.2M — $1.0M $75.0M $200M $0.0M $0.0M $0.0M $48.3M
Balance sheet
Cash and short-term investments $92.0M $436M $546M $607M $788M $428M $376M $681M $587M
Total debt — $54.5M $95.4M $93.9M $431M $431M $446M $437M $2.0B
Finance lease liabilities — — — $1.7M $1.5M — — — —
Current assets — $445M $569M $643M $889M $549M $478M $721M $798M
Current liabilities — $32.6M $60.4M $95.6M $135M $121M $144M $154M $288M
Inventory — — — — — — — $0.0M $26.8M
Property and equipment, net — $1.6M $5.6M $20.3M $30.1M $14.6M $11.8M $7.0M $5.4M
Intangible assets — — — $0.0M $44.9M $28.7M $26.3M $23.9M $28.1M
Total assets — $465M $632M $704M $1.0B $623M $546M $919M $936M
Total liabilities — $87.6M $156M $596M $1.9B $1.9B $1.9B $2.4B $3.0B
Preferred stock — — — — — — — $0.0M $0.0M
Shareholders' equity $85.9M $315M $408M $57.9M −$870M −$1.3B −$1.4B −$1.5B −$2.1B
Margins
Gross margin — — — — 95.5% 95.6% 73.7% 98.3% 95.8%
Operating margin — — −656.4% −5,752.0% −827.1% −659.6% −6,528.8% −267.2% −104.2%
EBITDA margin — — −654.3% −5,734.3% −818.7% −650.9% −6,458.9% −264.5% −103.2%
Net margin — — −711.5% −6,127.9% −841.2% −624.2% −7,021.9% −244.9% −146.0%
FCF margin — — −631.7% −4,936.7% −733.2% −546.5% −5,686.6% −235.1% −89.0%
Returns
Return on capital employed — −42.5% −46.6% −78.0% −65.7% −102.1% −150.9% −77.5% −80.8%
Return on equity −51.1% −84.6% −79.8% −216.8% — — — — —
Return on assets — −36.4% −52.6% −75.7% −68.3% −59.3% −111.7% −74.1% −79.0%
Return on tangible equity −35.6% −41.5% −63.8% −774.9% — — — — —
Growth
Revenue growth — — — −79.7% 745.1% 11.4% −88.0% 2,285.3% 126.3%
Share count change — 101.9% 70.2% 12.3% 22.3% 2.2% 10.4% 14.3% 2.9%
Financial health
Debt / equity — 0.2x 0.2x 1.6x — — — — —
Interest coverage −3,373.7x −72.1x −30.4x −12.9x −12.3x −6.4x −7.5x −6.5x −9.9x
Current ratio — 13.7x 9.4x 6.7x 6.6x 4.5x 3.3x 4.7x 2.8x
Quick ratio — 13.7x 9.4x 6.7x 6.6x 4.5x 3.3x 4.7x 2.7x
Capital allocation
Capex / revenue — — 6.5% 91.1% 19.0% 6.2% 14.0% 0.4% 0.2%
Stock comp / revenue — — 52.7% 708.7% 142.7% 117.9% 1,168.5% 43.2% 26.5%
Quality scores
Piotroski F-score — — 1.0 2.0 3.0 3.0 1.0 6.0 2.0
Altman Z'' — 5.7 2.9 −3.4 −4.1 −11.8 −19.5 −11.9 −14.2
Accruals ratio — −7.1% −6.4% −15.8% −10.3% −8.0% −21.5% −3.1% −30.9%

Source: SEC EDGAR XBRL filings (CIK 0001743881). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open